

6th December, 2024

BSE Limited

P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)- Update on Litigation

Dear Sir / Madam,

This is with reference to our earlier intimation dated 30th November, 2023, whereby we had informed the Stock Exchanges about a civil suit between Piramal Pharma Solutions Inc., wholly owned subsidiary of Piramal Pharma Limited (“Company”) and VetDC, Inc. (“VetDC”) with respect to damages claimed by VetDC on account VetDC’s rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc.

This is to inform that Piramal Pharma Solutions Inc. and VetDC, Inc. have entered into a settlement agreement dated 5th December, 2024 for an amount of USD 407,400. While the Company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC’s claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle. The Company shall have no responsibility for any other costs beyond the amount of USS 407,400.

This settlement will not have a significant impact on the financial position of the Company.

Request you to take the above on record.

Yours truly,

For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India

T +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com